Market Research Report
Cell Viability Assays Market - Growth, Trends, and Forecast (2019 - 2024)
|Published by||Mordor Intelligence LLP||Product code||907042|
|Published||Content info||115 Pages
Delivery time: 2-3 business days
|Cell Viability Assays Market - Growth, Trends, and Forecast (2019 - 2024)|
|Published: June 1, 2019||Content info: 115 Pages||
The major factors for the growth of the cell viability assays market include the growing burden of chronic and infectious diseases, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics.
Chronic diseases are among the primary global challenges, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. According to the World Health Organization (WHO), chronic diseases are expected to increase by 57% by 2020. Increased demand for healthcare systems due to chronic diseases has become a major concern. Furthermore, according to WHO in 2014, nearly 4 out of every 5 deaths in the world's developing countries resulted from chronic diseases. The Centers for Disease Control and Prevention (CDC ) states that in 2017, chronic diseases were the leading cause of death and disability in the United States, and 133 million Americans, i.e., 45% of the population, had at least one chronic disease. In addition, the rise of age- and lifestyle-related chronic diseases is increasing demand and spending for healthcare. In the emerging market, cancer and heart disease are becoming the main causes of death, as a result of urbanization, sedentary lifestyles, changing diets, rising obesity levels, and widespread availability of tobacco products. According to CDC estimates, these diseases are responsible for a majority of deaths in the United States, killing more than 1.7 million US citizens, annually. Thus, the growing burden of chronic diseases is expected to boost the cell-based research resulting in high growth of the market.
As per the scope of this report, cell viability assay is an assay to determine the ability of organs, cells or tissues to maintain or recover viability. This can assay mechanical activity, motility, contraction, etc. mitotic activity, mechanical activity, and motility are all used throughout a viability assay for this reason. Cell counting using the viability dyes which can provide both the rate of proliferation and also the percentage of viable cells.
The stem cell research segment is estimated to be the fastest growth by application owing to the rising research and development and funding from various organizations. According to the data available on the portal for National Institutes of Health (NIH), an estimated USD 1,748 million was granted for stem cell research in the fiscal year 2018. There are different cell-based treatment centers in the United States that have grown significantly over recent years. In 2015, there were more than 570 cell-based treatment centers across the United States. Thus, the increase in the number of centers has helped in driving stem cell research. Furthermore, the supports are increasing with the rising number of medical communities and government initiatives active in promoting the use of stem cells for the treatment of more than 100 diseases. Thus considering the all above mentioned factors the market is expected to witness high growth over the forecast period.
North America is found to hold a major share for the cell viability assays market and is expected to show a similar trend over the forecast period, without significant fluctuations. North America is dominating due to various factors like the growing incidence of chronic disease, growth in investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research. Various additional advantages such as the availability of insurance coverage for laboratory testing procedures, rising healthcare and R&D expenditure, and the presence of well-structured distribution channels in the region are also supporting the growth of the market. Furthermore, there is rising funding for the cell-based research in the United States which is expected to propel the overall growth of the cell viability assay market over the forecast period.
The market studied is a fragmented market owing to the presence of various small and large market players. Some of the market players are Abcam Plc, Becton Dickinson & Company, Bio-Rad Laboratories, Biotek Instruments, Creative Bioarray, GE Healthcare, Merck KGaA, Perkin Elmer, Promega Corporation, and Thermo Fischer Scientific Inc.